Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Synthorx, Inc.

https://synthorx.com

Latest From Synthorx, Inc.

Synthekine Joins Quest To Tame IL-2 In Cancer Therapies

First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.

Clinical Trials Companies

Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan

Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A. 

Financing Innovation

Sanofi Picks Venture Capitalist Ashrafian To Succeed Reed As R&D Head

The French drugmaker is banking on the wealth of expertise that Houman Ashrafian brings as both a scientist and biotech entrepreneur to drive forward its R&D efforts.

Leadership Research & Development

Sanofi Goes All In For Type 1 Diabetes With Provention Buy

Sanofi is taking full control of the recently approved type 1 diabetes prevention therapy Tzield by splashing out $2.9bn to acquire partner Provention.

M & A Metabolic Disorders
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Drug Discovery Tools
    • Drug Discovery Tools
      • ADMET
UsernamePublicRestriction

Register